Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cross-reactivity00:42

Cross-reactivity

31.2K
Overview
31.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.

Nature·2026
Same author

Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires.

PloS one·2026
Same author

Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.

JAMA·2026
Same author

Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters.

The Lancet. Infectious diseases·2026
Same author

Author Correction: Long COVID involves activation of proinflammatory and immune exhaustion pathways.

Nature immunology·2026
Same author

Utility of the US Preventive Services Task Force for Preeclampsia Risk Assessment and Aspirin Prophylaxis.

Obstetrical & gynecological survey·2026

相关实验视频

Updated: Jul 12, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.2K

通过SARS-CoV-2 Omicron亚变体BA.2.86的中和逃脱.

Ninaad Lasrado1, Ai-Ris Y Collier1, Nicole P Hachmann1

  • 1Beth Israel Deaconess Medical Center, Boston, MA, USA.

Vaccine
|October 23, 2023
PubMed
概括

与BA.2相比,新的SARS-CoV-2 BA.2.86变种显示了降低的中和抗体 (NAb) 标位. 然而,与BA.2.86相比,NAb标位与其他流通变体相比较,支持使用XBB.1.5助推器.

关键词:
BA.2.86 BA.2.86 的意思是中和抗体的抗体这就是SARS-CoV-2病毒.疫苗 疫苗 疫苗 疫苗它们是mRNARNA.

更多相关视频

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

1.7K

相关实验视频

Last Updated: Jul 12, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.2K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

11.8K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

1.7K

科学领域:

  • 病毒学 病毒学
  • 免疫学 免疫学 免疫学
  • 流行病学 流行病学

背景情况:

  • 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 持续演变,导致新的变种.
  • 该BA.2.86变种具有众多的尖端蛋白突变,引发了对免疫逃避的担忧.

研究的目的:

  • 评估SARS-CoV-2 BA.2.86变异突变对中和抗体 (NAb) 标位的影响.
  • 为了比较BA.2.86与其他流通的SARS-CoV-2变种的免疫性.

主要方法:

  • 对抗SARS-CoV-2变种中和抗体 (NAb) 标位的量化.
  • 在接种疫苗的个体中,先前感染XBB.1.5的和没有感染的NAb反应的比较.

主要成果:

  • 针对BA.2.86的NAb标位明显低于针对BA.2.
  • 与BA.2.86相比,NAb标位与XBB.1.5,EG.5.1和FL.1.5.1.1相比类似或更高.
  • 疫苗接种过XBB.1.5感染病史的个体对所有测试变体的NAb标位都较高.

结论:

  • 这种BA.2.86变种表现出来自中和抗体的部分免疫逃脱.
  • 单价XBB.1.5mRNA增强剂可能会提供针对当前和新出现的SARS-CoV-2变种的交叉保护.